4 & 5 February, 2025  |  Free Online Conference
Welcome to the Antimicrobial Chemotherapy Conference 2025.
This open-access, virtual conference was jointly organised by BSAC and GARDP. For ACC2025, the collaborating organisations were CEPID-ARIES and Fiocruz. This conference is RCPath CPD accredited (8 credits).

ACC2025 Programme

Click here to explore our past conferences: ACC2024, ACC2023, ACC2022. Recordings and programmes of our earlier conferences (2019, 2021) can be found here).

Select to see different time zones. Default is GMT. Time Zone Converter – Time Difference Calculator


SESSION ONE: KEYNOTE PRESENTATION

View session one. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Dr Mike Allen, Regional Medical Advisor (Antibiotics), MSD UK & BSAC General Secretary - View Bio

Global Challenges and Goals for AMR – Reflections from the UNGA High Level Meeting

Dr Ana Cristina Gales, Federal University of São Paulo, Brazil - View Bio

Q&A

SESSION TWO: Drug discovery: new targets and new chemistry

View session two. This video consists of the following presentations:

Watch Presentation

Antibiotic class with potent in vivo activity targeting lipopolysaccharide synthesis in Gram-negative bacteria

Dr Douglas Huseby, Uppsala University - View Bio

The Ersilia Model Hub: Open Source AI for Antimicrobial Drug Discovery

Dr Miquel Duran-Frigola, Ersilia Open Source Initiative - View Bio

Immunotherapy focused on infectious diseases

Pamela Brown, Centauri Therapeutics Ltd - View Bio

Q&A

SESSION THREE: Preclinical antimicrobial development

View session three. This video consists of the following presentations:

Watch Presentation

FabI inhibitor for Neisseria gonorrhoeae (Debio1453)

Dr David Cameron, Debiopharm - View Bio

EBL-1463, a non-beta-lactam PBP inhibitor impervious to beta-lactamase hydrolysis for the treatment of CRE infections

Dr François Moreau, Tamrisa Innovation - View Bio

An Immune Approach for the Treatment of Sepsis

Dr Jessica Field, Cellics Therapeutics - View Bio

Q&A

SESSION FOUR: Panel discussion - The antifungal development pipeline

View session four. This video consists of the following presentations:

Watch Presentation

Panel discussion

Dr Leah Cowen, University of Toronto, Canada - View Bio

Dr Maurizio Del Poeta, Stony Brook University, USA - View Bio

Q&A

Closing remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer - View Bio

SESSION FIVE: Clinical development and use of new agents

View session five. This video consists of the following presentations:

Watch Presentation

Introductory remarks

Dr Christopher Longshaw, Shionogi BV & BSAC Honorary Treasurer - View Bio

Development pathways in antibiotic development - This presentation has been developed by Pfizer Inc

Halley Rogers, Pfizer Inc - View Bio

The challenges and opportunities in the preclinical development of cefepime-enmetazobactam

Dr Maneesh Paul, Microvioma - View Bio

The challenges and opportunities of the development pathway for Phage therapy

Dr Ariel Cohen, BiomX/Adaptive Phage Therapeutics - View Bio

Q&A

SESSION SIX: Oral poster presentations

View session six. This video consists of the following presentations:

Watch Presentation

Leveraging stem cell technology to identify new treatment options for nontuberculous mycobacteria

Dr Sohinee Sarkar, Murdoch Children's Research Institute, Australia

Utilising actinobacteria diversity in the Great Salt Plains to look for novel TB therapeutics

Dr Amanda Jones, Northumbria University, Newcastle upon Tyne

Building an on-panel enzyme detection system to reveal and resolve clinically problematic beta-lactamases in Gram negative bacteria

Dr Nicole Jackson, BioAmp Diagnostics

Functional high-throughput screening identifies microRNAs regulating infection by Staphylococcus aureus

Dr Caio Haddad Franco, AccelBio Collaborative Laboratory, University of Coimbra

Computational study to identify novel Metallo-β-lactamases inhibitors using virtual screening, molecular docking, dynamic simulations, and ADMET prediction

Fatima Mourabiti, University of Casablanca

Q&A

SESSION SEVEN: Control of infectious diseases with biotherapeutics and beyond

View session seven. This video consists of the following presentations:

Watch Presentation

The role of vaccines to tackle AMR

Professor Angela Brueggemann, University of Oxford - View Bio

Therapeutic antibodies and infectious diseases

Dr Liise-anne Pirofski, Albert Einstein College of Medicine and Montefiore Medical Center - View Bio

Jumbo Bacteriophages for IPC

Dr Gregorio Iraola, Kinzbio - View Bio

Q&A

SESSION EIGHT: Panel discussion - Acceleration of development/access of POCTs for STI management

View session eight. This video consists of the following presentations:

Watch Presentation

Moving from syndromic to aetiological approaches for STI management: a focus on implementation challenges and opportunities in LMIC settings

Dr Chido Dziva Chikwari, London School of Hygiene & Tropical Medicine - View Bio

Developing a low cost N. gonorrhoeae lateral flow assay: challenges and opportunities

Dr Cecilia Ferreyra, FINDcec - View Bio

Developer’s experience of developing a test for N. gonorrhoeae and guidance for POCT developers on ceftriaxone-resistant N. gonorrhoeae targets

Dr Alex Trick, Prompt Diagnostics - View Bio

Clinical use and uptake of STI POCTs in LMICs

Dr Yukari Manabe, Johns Hopkins Center for Innovative Diagnostics for Infectious Diseases - View Bio

Panel discussion

Q&A

Closing remarks

Dr Alison Luckey, GARDP - View Bio